News >

Concurrent Chemoradiation, Radical Cystectomy Demonstrate Similar Median OS Rates in Urothelial Cancer

Tony Berberabe, MPH @OncBiz_Wiz
Published: Friday, Oct 14, 2016

Jim Zhong, MD

Jim Zhong, MD

In a propensity-matched analysis of a national cancer registry, patients who underwent radical cystectomy or concurrent chemoradiation to treat urothelial cancer demonstrated statistically similar median overall survival (OS) rates. Further analysis suggests that the hazard ratios between the two treatments change over time and is hypothesis generating, said Jim Zhong, MD, of Winship Cancer Institute at Emory University.

Those patients with American Joint Committee on Cancer tumor stages II-III, N0, M0, urothelial cancer were included in the analysis. Zhong said only patients treated with definitive intent with either radical cystectomy or concurrent chemotherapy and radiation were included. In addition, only patients who underwent a maximal tumor resection, followed by a definitive course of radiation with chemotherapy were included in the bladder preservation chemoradiation arm.

The primary endpoint of the study was OS and researchers used Kaplan-Meier, log-rank test, and multivariable Cox proportional hazards regression for statistical analysis. Zhong reported that propensity score matching was used to reduce treatment selection bias. Also, a time-varying covariate analysis was generated to evaluate interactions between treatment and survival time.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication